Explore
Validate
Learn66678-1-Ig
antibody from Proteintech Group
Targeting: FOLH1
FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66678-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- PSMA/GCPII antibody
- Antibody type
- Monoclonal
- Description
- PSMA/GCPII antibody (Cat. #66678-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, Rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 3G4E12
- Vial size
- 20ul, 150ul
Submitted references PAM-assembled CRISPR-Cas12a activation-based fluorescent and colorimetric dual-modal biosensor for detecting prostate cancer exosomes.
A Novel Type of PSMA-Targeting Ligands via β-Branched Aromatic α-Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity.
Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization.
Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer.
Design, synthesis and biological evaluation of a novel PSMA-PI3K small molecule drug conjugate.
Cancer cell's neuroendocrine feature can be acquired through cell-cell fusion during cancer-neural stem cell interaction.
Miao Y, Wang C, Peng Y, Sun X, Zheng Z, Zhang Q, Cheng W, Li J
Biosensors & bioelectronics 2026 Jul 15;304:118635
Biosensors & bioelectronics 2026 Jul 15;304:118635
A Novel Type of PSMA-Targeting Ligands via β-Branched Aromatic α-Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity.
Liu ZX, Chen X, Gao X, Zhang S, Xing C, Wang R, Hu K, Yang LC
Journal of medicinal chemistry 2025 Sep 25;68(18):19661-19672
Journal of medicinal chemistry 2025 Sep 25;68(18):19661-19672
Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization.
Wang Z, Ge Q, Anwaier A, Liu S, Tian X, Zhang Z, Feng T, Hong Z, Ye D, Xu W, Qin X
Molecular cancer 2025 Oct 2;24(1):238
Molecular cancer 2025 Oct 2;24(1):238
Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer.
Kirschenbaum A, Cheung P, Rajagopalan V, Yao S, Milgrim L, Kyprianou N, Levine AC
American journal of clinical and experimental urology 2024;12(5):255-265
American journal of clinical and experimental urology 2024;12(5):255-265
Design, synthesis and biological evaluation of a novel PSMA-PI3K small molecule drug conjugate.
Peng S, Li H, Cui W, Xiong T, Hu J, Qi H, Lin S, Wu D, Ji M, Xu H
RSC medicinal chemistry 2024 Aug 24;15(10):3485-94
RSC medicinal chemistry 2024 Aug 24;15(10):3485-94
Cancer cell's neuroendocrine feature can be acquired through cell-cell fusion during cancer-neural stem cell interaction.
Yin L, Hu P, Shi X, Qian W, Zhau HE, Pandol SJ, Lewis MS, Chung LWK, Wang R
Scientific reports 2020 Jan 27;10(1):1216
Scientific reports 2020 Jan 27;10(1):1216
No comments: Submit comment
No validations: Submit validation data